Stay updated on Nivolumab ± Ipilimumab in Gastrointestinal Stromal Tumor Clinical Trial

Sign up to get notified when there's something new on the Nivolumab ± Ipilimumab in Gastrointestinal Stromal Tumor Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab ± Ipilimumab in Gastrointestinal Stromal Tumor Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The value on the webpage has changed from 'No Results Posted' to 'Results Submitted,' indicating that the study results have been submitted for review and publication.
    Difference
    0.1%
    Check dated 2024-06-11T20:57:36.000Z thumbnail image
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record of a randomized phase II trial investigating the efficacy of nivolumab with or without ipilimumab in treating patients with gastrointestinal stromal tumor that has spread or cannot be surgically removed.
    Difference
    0.1%
    Check dated 2024-06-06T14:28:59.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    50%
    Check dated 2024-05-22T20:58:41.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:31:41.000Z thumbnail image

Stay in the know with updates to Nivolumab ± Ipilimumab in Gastrointestinal Stromal Tumor Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab ± Ipilimumab in Gastrointestinal Stromal Tumor Clinical Trial page.